Xinhua pharmaceutical gains approval for oseltamivir phosphate oral suspension

Shandong Xinhua Pharmaceutical Co., Ltd. announced it has received a drug registration certificate from the National Medical Products Administration for its oseltamivir phosphate for oral suspension. The product, a Category 3 chemical drug, is for the treatment of influenza A and B in patients aged 2 weeks and older, and for prevention in individuals aged 1 year and older.

The drug, approved under national drug approval number H20256303, will undergo pre-marketing checks for compliance with good manufacturing practices. In 2024, sales of oseltamivir phosphate-related preparations in public medical institutions in China were approximately RMB 5.9 bn.

The acquisition of this registration certificate is expected to enrich Xinhua Pharmaceutical's antiviral drug product line and enhance its overall competitiveness. The company noted that drug sales are subject to uncertainties due to policy changes, tender procurements, and market environment fluctuations in the domestic pharmaceutical industry.